Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PXMD PaxMedica
2.150
-0.230-9.66%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
57.16% 2.69M -53.09% 927.39K 16.89% 2M 29.32% 7.2M
Selling and administrative expenses
85.37% 2.37M -28.61% 775.96K -27.44% 933.82K 7.44% 4.97M
-General and administrative expense
85.37% 2.37M -28.61% 775.96K -27.44% 933.82K 7.44% 4.97M
Research and development costs
-25.21% 327.27K -82.98% 151.43K 150.19% 1.07M 137.47% 2.22M
Operating profit
-57.16% -2.69M 53.09% -927.39K -16.89% -2M -29.32% -7.2M
Net non-operating interest income expense
-89.54K -303.01K 0 -323.21% -2.81M
Non-operating interest expense
-- 1.31K -- 0 -- 0 360.39% 2.81M
Total other finance cost
-- 88.23K -- 303.01K -- -- -- --
Other net income (expense)
-521.80% -8.68M 130.07% 1.25M 243.29% 3.87M 85.89% -225.32K
Gain on sale of security
54.72% -357.41K 99.90% -3.16K 592.70% 2.23M 70.86% -458.56K
Special income (charges)
-- -3.94K -- 0 -- 0 357.22% 59.89K
-Less:Other special charges
-- 3.94K -- -- -- -- -357.22% -59.89K
Other non- operating income (expenses)
-1,271.71% -8.32M 239.31% 1.25M 170.87% 1.63M -- 173.35K
Income before tax
-268.53% -11.46M 100.31% 19.03K 125.81% 1.86M -30.70% -10.23M
Income tax
Net income
-268.53% -11.46M 100.31% 19.03K 125.81% 1.86M -30.70% -10.23M
Net income continuous Operations
-268.53% -11.46M 100.31% 19.03K 125.81% 1.86M -30.70% -10.23M
Minority interest income
Net income attributable to the parent company
-268.53% -11.46M 100.31% 19.03K 125.81% 1.86M -30.70% -10.23M
Preferred stock dividends
Other preferred stock dividends
5.83K 603.93K
Net income attributable to common stockholders
-268.53% -11.46M 100.22% 13.2K 117.44% 1.26M -10.01% -10.23M
Basic earnings per share
-105.10% -0.87 100.22% 0.0018 117.48% 0.126 19.47% -1.021
Diluted earnings per share
-105.10% -0.87 100.22% 0.0018 94.87% -0.037 19.47% -1.021
Dividend per share
Currency Unit
USDUSDUSDUSD
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
PaxMedica, Inc. is an early clinical stage biopharmaceutical company. It focuses on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder and Fragile X syndrome tremor-ataxia. The company was founded in April 5, 2018 and is headquartered in Woodcliff Lake, NJ.
CEO: Mr. Howard J. Weisman
Market: NASDAQ
Listing Date: 08/26/2022
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist